- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.03. | Alcon claims control of cell therapy firm Aurion | ||
| 27.03. | FDA fast-tracks Sanofi's experimental chlamydia vaccine | ||
| 27.03. | BIO rings alarm bells over Trump's pharma tariffs | ||
| 27.03. | FDA clears first treatment for Prader-Willi syndrome | ||
| 27.03. | J&J throws the gauntlet down to AZ with new survival data | ||
| 26.03. | GSK ends decades-long hiatus in oral antibiotics for UTIs | ||
| 26.03. | Character raises $93m for eye drugs, plus other financings | ||
| 26.03. | UK sets aside £2m for digitally-enhanced dementia tests | ||
| 26.03. | End of the line for Cassava's troubled Alzheimer's programme | ||
| 26.03. | Senate confirms Trump picks for FDA and NIH | ||
| 25.03. | MSD licenses Lp(a) heart drug from Hengrui in $2bn deal | ||
| 25.03. | FDA starts review of Sanofi's MS hope tolebrutinib | ||
| 25.03. | GSK taps into UK health data for dementia study | ||
| 25.03. | Trump nominates Susan Monarez as CDC director | ||
| 25.03. | AbbVie sues Genmab, claiming trade secrets theft | ||
| 24.03. | MIT team develops 'years-long' drug delivery tech | ||
| 24.03. | Novo Nordisk looks east for another obesity therapy | ||
| 24.03. | Phase 3 readout puts Opthea at risk of insolvency | ||
| 24.03. | Augustine decloaks with $85m for nerve disease programme | ||
| 24.03. | 23andMe files for bankruptcy protection | ||
| 21.03. | EMA panel endorses AI for MASH clinical trials | ||
| 21.03. | AZ builds in China, as J&J ramps up its US investments | ||
| 21.03. | Fabhalta is first FDA-approved therapy for rare disease C3G | ||
| 21.03. | J&J adds to IL-23 options in Crohn's after FDA approval | ||
| 21.03. | Alnylam joins three-way contest in ATTR cardiomyopathy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
